Industry underdogs look giant challenges in the eye
How the generic drug industry can submit more complete applications
Investments in biologic capability are projected to fuel industry innovation
Although FDA can’t control prescription drug pricing, it can and will facilitate increased drug competition through faster approval of lower-cost, generic medicines
White Papers: In Depth Research
Posted: Feb 08, 2017
As pharma companies look more and more to biologics for their next potential blockbusters, they must face the challenges surrounding these products' scientific complexity and sophisticated development.